SIRT1 and acute myeloid leukemia: The SIRT1 mRNA and protein levels were also significantly lower in AML cells treated with Ara-c or sorafenib combined with chidamide compared with cells treated with only Ara-c or sorafenib (Tables 5, 6 and Figure 5).